Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Meda In-Licenses Ceplene Rights From EpiCept
Ceplene is indicated for remission maintenance therapy and prevention of relapse in adult patients with acute myeloid leukemia (AML). In a multicenter study, Ceplene met its primary endpoint
Ceplene is indicated for remission maintenance therapy and prevention of relapse in adult patients with acute myeloid leukemia (AML). In a multicenter study, Ceplene met its primary endpoint
As per the collaboration, the current scientific knowledge on Ipsogen’s MapQuant Dx Grade Genomic, HER2 and HR tests, will be increased to new data established from a large
Tom started his career as a Financial Controller in Ecco in 1993. In 1996, Tom joined Danfoss, where he held different financial management roles and lived both in
In the alliance, Galapagos will apply its target discovery platform to discover novel COPD targets. Galapagos will be responsible for the discovery and development of new small molecule
Reportedly, Albemarle’s custom manufacturing business unit, Fine Chemistry Services (FCS) is designed and built the facility using a combination of new and existing equipment at Albemarle’s Pasadena, Texas
AMR101 is an ultra-pure omega-3 form being developed with ethyl ester of eicosapentaenoic acid (ethyl-EPA). Numerous independent studies have demonstrated the safety, tolerability and efficacy of ethyl-EPA in
In May 2009, the company had announced that the efficacy portion of its Phase 3 Freedom-301 clinical study of Levadex met all four primary endpoints. The company had
The company said that the final Prelude device replaces the prototype device used in earlier clinical trials and will be tested in the near-term in a study using
Edward Lanphier, president and CEO of Sangamo, said: “We enter 2010 with a strong balance sheet and a robust clinical pipeline. With the initiation of these two new
The company claims that patients who attempted intercourse within 15 minutes of dosing were successful 67%, 69% and 72% of the time on 50, 100 and 200mg of